Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat.

"CONFLICT OF INTEREST STATEMENT Danny M. Cohn has received speaker, consultancy, and/or advisory board fees from BioCryst, CSL Behring, Ionis Pharmaceuticals, KalVista, Pharvaris, and Takeda; Danny M. Cohn is also a member of the HAE International Medical Advisory Panel. Emel Aygören‐Pürsün has received grants, speaker fees, consultancy fees, travel support, advisory board fees, and/or honoraria for manuscript writing and educational events from BioCryst, BioMarin, Centogene, CSL Behring, KalVista, Pharming, Pharvaris, and Shire/Takeda. Jonathan A. Bernstein has received grants and/or speaker/consultancy fees from and served on advisory boards for Astria, BioCryst, BioMarin, CSL Behring, Cycle Pharmaceuticals, Incyte, KalVista, Ono, Pharming, Pharvaris, and Shire/Takeda; Jonathan A. Bernstein is also a member of the medical advisory board for the US HAE Association. Henriette Farkas has received research grants from CSL Behring, Pharming, and Takeda; and has served as an advisor and speaker for these companies and for Astria, BioCryst, KalVista, and Ono. William R. Lumry has received grants and/or speaker/consultancy fees from and/or served on advisory boards for Astria, BioCryst, BioMarin, CSL Behring, Fresenius Kabi, Intellia, Ionis, KalVista, Pharming, and Takeda; William R. Lumry is also a member of the medical advisory board for the US HAE Association. Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Arcensus, Astria, BioCryst, Centogene, CSL Behring, KalVista, Pharming, Pharvaris, and Takeda. Andrea Zanichelli has received speaker/consultancy fees from BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, and Takeda. Matthew Iverson, James Hao, Michael D. Smith, Christopher M. Yea, and Paul K. Audhya are employees of KalVista Pharmaceuticals. Marc A. Riedl has received research funding from BioCryst, BioMarin, CSL Behring, Ionis, KalVista, Pharvaris, and Takeda, and advisor and/or speaker fees from Astria, Biocryst, Biomarin, CSL Behring, Cycle, Intellia, Ipsen, KalVista, Ono, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi‐Regeneron, Spark, and Takeda."

"Scientific editorial review was provided by Zara Melyan, KalVista Pharmaceuticals. Medical writing assistance was provided under the direction of the authors by Jackie Highland, PhD, CMPP, of ArticulateScience, LLC, and was supported by KalVista Pharmaceuticals. These studies were funded by KalVista Pharmaceuticals."